MedPath

AN INVESTIGATOR INITIATED STUDY TO OBSERVE AND EVALUATE THE INCIDENCE OF EGFR MUTATIONS IN ADULT INDIAN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Not Applicable
Conditions
Health Condition 1: null- Non-small cell lung Cancer
Registration Number
CTRI/2012/05/002665
Lead Sponsor
Dr Senthil Rajappa
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
150
Inclusion Criteria

1.Subjects with non-small cell lung Cancer.

2.Subjects of Physicians who are willing to share their subjectsâ?? data for this study.

3.Ethics Committeeâ??s permission to conduct the analysis on a retrospective manner without the physical consent of the subjects who have contributed to the existing data from their respective institutions

Exclusion Criteria

Not provided

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of EGFR mutationsTimepoint: 10 Months
Secondary Outcome Measures
NameTimeMethod
ï??Types of mutations - incorrelation with demography, clinical parameters, etc. of the following: <br/ ><br> <br/ ><br>â?¢% of Exon 19 Deletions <br/ ><br>â?¢% of EGFR L858R (Exon 21) mutations <br/ ><br>â?¢% of EGFR T790M (Exon 20) mutations <br/ ><br>â?¢% of EGFR L861Q (Exon 21) mutations <br/ ><br>â?¢% of EGFR G719X (Exon 18) mutations <br/ ><br>â?¢% of EGFR S7681 (Exon 20) mutations <br/ ><br>â?¢% of Exon 20 Insertions <br/ ><br>Timepoint: After Ten Months <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath